HIV-Associated Tuberculosis: Diagnostic and Treatment Challenges

 

 Buy Article Permissions and Reprints

ABSTRACT

Tuberculosis (TB) and the human immunodeficiency virus (HIV) are, individually, two of the world's greatest ongoing public health threats. In combination, the two diseases can be even more devastating. HIV significantly increases an individual's chances of reactivation of latent TB infection and progression to active TB disease. HIV's associated immunosuppression makes it more difficult to diagnose active TB due to a higher likelihood of atypical and extrapulmonary presentation and poorer performance of standard diagnostic tools. TB is the major cause of death in individuals infected with HIV, and the combination of both illnesses creates unique treatment challenges for providers due to interactions between antituberculous and antiretroviral medications, overlapping drug toxicities, and the immune reconstitution inflammatory syndrome. Magnifying these challenges even further is the fact that much of the burden of TB/HIV coinfection exists in some of the world's most resource-limited settings. Concerted efforts are needed to identify rapid and accurate diagnostic tools for active TB disease and latent TB infection (LTBI) that are practical and inexpensive and that perform well in individuals with HIV infection. Also needed are effective and feasible strategies to optimize management of both conditions in the coinfected patient.

REFERENCES

• 1 World Health Organization .Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report. Geneva, Switzerland; WHO 2008
  Google Scholar
• 2 UNAIDS .AIDS Epidemic Update. December 2007 Geneva, Switzerland; UNAIDS
  Google Scholar
• 3 Selwyn P A, Hartel D, Lewis V A et al.. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.  , [see comment] N Engl J Med. 1989;  320 545-550
  CrossrefPubMedGoogle Scholar
• 4 Daley C L, Small P M, Schecter G F et al.. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms.  N Engl J Med. 1992;  326 231-235
  CrossrefPubMedGoogle Scholar
• 5 Antonucci G, Girardi E, Raviglione M C, Ippolito G. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA).  JAMA. 1995;  274 143-148
  CrossrefPubMedGoogle Scholar
• 6 McIlleron H, Meintjes G, Burman W J, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.  J Infect Dis. 2007;  196(Suppl 1) S63-S75
  CrossrefPubMedGoogle Scholar
• 7 World Health Organization .Anti-tuberculosis Drug Resistance in the World: Fourth Global Report. Geneva, Switzerland; WHO 2008
  Google Scholar
• 8 Gandhi N R, Moll A, Sturm A W et al.. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.  , [see comment] Lancet. 2006;  368 1575-1580
  CrossrefPubMedGoogle Scholar
• 9 Siddiqi K, Lambert M L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence.  Lancet Infect Dis. 2003;  3 288-296
  CrossrefPubMedGoogle Scholar
• 10 Colebunders R L, Ryder R W, Nzilambi N et al.. HIV infection in patients with tuberculosis in Kinshasa, Zaire.  Am Rev Respir Dis. 1989;  139 1082-1085
  PubMedGoogle Scholar
• 11 Geng E, Kreiswirth B, Burzynski J, Schluger N W. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study.  JAMA. 2005;  293 2740-2745
  CrossrefPubMedGoogle Scholar
• 12 Harries A D, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa.  Bull World Health Organ. 1998;  76 651-662
  PubMedGoogle Scholar
• 13 De Cock K M, Soro B, Coulibaly I M, Lucas S B. Tuberculosis and HIV infection in sub-Saharan Africa.  JAMA. 1992;  268 1581-1587
  CrossrefPubMedGoogle Scholar
• 14 Small P M, Schecter G F, Goodman P C, Sande M A, Chaisson R E, Hopewell P C. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.  N Engl J Med. 1991;  324 289-294
  PubMedGoogle Scholar
• 15 Hargreaves N J, Kadzakumanja O, Whitty C J, Salaniponi F M, Harries A D, Squire S B. 'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence.  Int J Tuberc Lung Dis. 2001;  5 847-854
  PubMedGoogle Scholar
• 16 Harries A D, Hargreaves N J, Gausi F, Kwanjana J H, Salaniponi F M. High early death rate in tuberculosis patients in Malawi.  Int J Tuberc Lung Dis. 2001;  5 1000-1005
  PubMedGoogle Scholar
• 17 Mtei L, Matee M, Herfort O et al.. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania.  , [see comment] Clin Infect Dis. 2005;  40 1500-1507
  CrossrefPubMedGoogle Scholar
• 18 Day J H, Charalambous S, Fielding K L, Hayes R J, Churchyard G J, Grant A D. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa.  Int J Tuberc Lung Dis. 2006;  10 523-529
  PubMedGoogle Scholar
• 19 Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G. Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy.  Int J Tuberc Lung Dis. 2004;  8 792-795
  PubMedGoogle Scholar
• 20 Cowie R L, Escreet B C. The diagnosis of pulmonary tuberculosis.  S Afr Med J. 1980;  57 75-77
  PubMedGoogle Scholar
• 21 Singh K K, Dong Y, Hinds L et al.. Combined use of serum and urinary antibody for diagnosis of tuberculosis.  J Infect Dis. 2003;  188 371-377
  CrossrefPubMedGoogle Scholar
• 22 Singh K K, Zhang X, Patibandla A S, Chien Jr P, Laal S. Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences.  Infect Immun. 2001;  69 4185-4191
  CrossrefPubMedGoogle Scholar
• 23 Perkins M D, Conde M B, Martins M, Kritski A L. Serologic diagnosis of tuberculosis using a simple commercial multiantigen assay.  Chest. 2003;  123 107-112
  CrossrefPubMedGoogle Scholar
• 24 Breen R A, Hardy G A, Perrin F M et al.. Rapid diagnosis of smear-negative tuberculosis using immunology and microbiology with induced sputum in HIV-infected and uninfected individuals.  PLoS One. 2007;  2 e1335
  CrossrefPubMedGoogle Scholar
• 25 Ling D I, Flores L L, Riley L W, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression.  PLoS One. 2008;  3 e1536
  CrossrefPubMedGoogle Scholar
• 26 Kibiki G S, Mulder B, van der Ven A J et al.. Laboratory diagnosis of pulmonary tuberculosis in TB and HIV endemic settings and the contribution of real time PCR for M. tuberculosis in bronchoalveolar lavage fluid.  Trop Med Int Health. 2007;  12 1210-1217
  PubMedGoogle Scholar
• 27 Onyebujoh P C, Ribeiro I, Whalen C C. Treatment options for HIV-associated tuberculosis.  J Infect Dis. 2007;  196(Suppl 1) S35-S45
  CrossrefPubMedGoogle Scholar
• 28 Spigelman M K. New tuberculosis therapeutics: a growing pipeline.  J Infect Dis. 2007;  196(Suppl 1) S28-S34
  CrossrefPubMedGoogle Scholar
• 29 World Health Organization .Treatment of Tuberculosis: Guidelines for National Programmes 3rd ed. (English). WHO/CDS/TB/2003.313. Geneva, Switzerland; WHO 2003
  Google Scholar
• 30 Blumberg H M, Burman W J, Chaisson R E et al.. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.  , [see comment] Am J Respir Crit Care Med. 2003;  167 603-662
  CrossrefPubMedGoogle Scholar
• 31 World Health Organization .TB/HIV: A Clinical Manual. 2nd ed. Geneva, Switzerland; WHO 2004
  Google Scholar
• 32 World Health Organization . Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach: executive summary. April 2002.  IAPAC Mon. 2002;  8 168-175
  PubMedGoogle Scholar
• 33 Dean G L, Edwards S G, Ives N J et al.. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.  , [see comment] AIDS. 2002;  16 75-83
  PubMedGoogle Scholar
• 34 Dheda K, Lampe F C, Johnson M A, Lipman M C. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.  , [see comment] J Infect Dis. 2004;  190 1670-1676
  CrossrefPubMedGoogle Scholar
• 35 Centers for Disease Control and Prevention .Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2007. Available at: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Accessed May 31, 2008
  Google Scholar
• 36 Lopez-Cortes L F, Ruiz-Valderas R, Viciana P et al.. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.  Clin Pharmacokinet. 2002;  41 681-690
  PubMedGoogle Scholar
• 37 Jack C, Lalloo U, Abdool-Karim Q et al.. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.  J Acquir Immune Defic Syndr. 2004;  36 929-934
  CrossrefPubMedGoogle Scholar
• 38 Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.  HIV Med. 2008;  9 294-299
  CrossrefPubMedGoogle Scholar
• 39 Narita M, Ashkin D, Hollender E S, Pitchenik A E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.  Am J Respir Crit Care Med. 1998;  158 157-161
  CrossrefPubMedGoogle Scholar
• 40 Lawn S D, Bekker L G, Miller R F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.  , [see comment] Lancet Infect Dis. 2005;  5 361-373
  CrossrefPubMedGoogle Scholar
• 41 Burman W, Weis S, Vernon A et al.. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.  Int J Tuberc Lung Dis. 2007;  11 1282-1289
  PubMedGoogle Scholar
• 42 Bock N N, Jensen P A, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment.  J Infect Dis. 2007;  196(Suppl 1) S108-S113
  CrossrefPubMedGoogle Scholar
• 43 Wells C D, Cegielski J P, Nelson L J et al.. HIV infection and multidrug-resistant tuberculosis: the perfect storm.  J Infect Dis. 2007;  196(Suppl 1) S86-S107
  CrossrefPubMedGoogle Scholar
• 44 Andrews J R, Shah N S, Gandhi N, Moll T, Friedland G. Tugela Ferry Care and Research C: multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.  J Infect Dis. 2007;  196(Suppl 3) S482-S490
  CrossrefPubMedGoogle Scholar
• 45 Screening for tuberculosis and tuberculous infection in high-risk populations. Recommendations of the Advisory Committee for Elimination of Tuberculosis.  MMWR Recomm Rep. 1990;  39(RR-8) 1-7
  PubMedGoogle Scholar
• 46 Markowitz N, Hansen N I, Wilcosky T C et al.. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group.  , [see comment] Ann Intern Med. 1993;  119 185-193
  CrossrefPubMedGoogle Scholar
• 47 Guelar A, Gatell J M, Verdejo J et al.. A prospective study of the risk of tuberculosis among HIV-infected patients.  AIDS. 1993;  7 1345-1349
  PubMedGoogle Scholar
• 48 Louise R, Skjøt R, Agger E, Anderson P. Antigen discovery and tuberculosis vaccine development in the post-genomic era.  Scand J Infect Dis. 2001;  33 643-647
  CrossrefPubMedGoogle Scholar
• 49 Gey Van Pittius N C, Gamieldien J, Hide W, Brown G D, Siezen R J, Beyers A D. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G + C gram-positive bacteria.  Genome Biol. 2001;  2(10) , RESEARCH0044
  PubMedGoogle Scholar
• 50 Mori T, Sakatani M, Yamagishi F et al.. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens.  , [see comment] Am J Respir Crit Care Med. 2004;  170 59-64
  CrossrefPubMedGoogle Scholar
• 51 Mazurek G H, Jereb J, Lobue P et al.. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. [erratum appears in MMWR Morb Mortal Wkly Rep. 2005 Dec 23;54(50):1288].  MMWR Recomm Rep. 2005;  54(RR-15) 49-55
  PubMedGoogle Scholar
• 52 Tsiouris S J, Coetzee D, Toro P L, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis.  J Clin Microbiol. 2006;  44 2844-2850
  CrossrefPubMedGoogle Scholar
• 53 Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients.  Eur Respir J. 2007;  30 945-950
  CrossrefPubMedGoogle Scholar
• 54 Luetkemeyer A F, Charlebois E D, Flores L L et al.. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.  Am J Respir Crit Care Med. 2007;  175 737-742
  CrossrefPubMedGoogle Scholar
• 55 Dheda K, Lalvani A, Miller R F et al.. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count.  , [see comment] AIDS. 2005;  19 2038-2041
  PubMedGoogle Scholar
• 56 Hoffmann M, Reichmuth M, Fantelli K et al.. Conventional tuberculin skin testing versus T-cell-based assays in the diagnosis of latent tuberculosis infection in HIV-positive patients.  , [comment] AIDS. 2007;  21 390-392
  PubMedGoogle Scholar
• 57 Rangaka M X, Diwakar L, Seldon R et al.. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans.  Clin Infect Dis. 2007;  44 1639-1646
  CrossrefPubMedGoogle Scholar
• 58 Karam F, Mbow F, Fletcher H et al.. Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression.  PLoS One. 2008;  3 e1441
  CrossrefPubMedGoogle Scholar
• 59 Shieh F K, Snyder G, Horsburgh C R, Bernardo J, Murphy C, Saukkonen J J. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey.  Am J Respir Crit Care Med. 2006;  174 717-721
  CrossrefPubMedGoogle Scholar
• 60 Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman L B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.  , [see comment] Chest. 2006;  130 1712-1717
  CrossrefPubMedGoogle Scholar
• 61 Hawken M P, Muhindi D W. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.  Int J Tuberc Lung Dis. 1999;  3 646-650
  PubMedGoogle Scholar
• 62 Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons.  Cochrane Database Syst Rev. 2000;  (4) CD000171 , Update in: Cochrane Database Syst Rev 2004;(1):CD000171; PMID: 14973947
  PubMedGoogle Scholar
• 63 Bell J C, Rose D N, Sacks H S. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective.  , [see comment] AIDS. 1999;  13 1549-1556
  CrossrefPubMedGoogle Scholar
• 64 Johnson J L, Okwera A, Hom D L et al.. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.  AIDS. 2001;  15 2137-2147
  CrossrefPubMedGoogle Scholar
• 65 Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.  , [see comment][erratum appears in Lancet 2002 Jun 15;359(9323):2120] Lancet. 2001;  358 1687-1693
  CrossrefPubMedGoogle Scholar
• 66 Gasana M, Vandebriel G, Kabanda G et al.. Integrating tuberculosis and HIV care in rural Rwanda.  Int J Tuberc Lung Dis. 2008;  12(3 Suppl 1) S39-S43
  PubMedGoogle Scholar

Simon J TsiourisM.D. M.P.H. 

Division of Infectious Diseases, College of Physicians and Surgeons, Columbia University

622 West 168th St., PH 8 – 876W, New York, NY 10032

Email: st326@columbia.edu